New England Drug Metabolism Discussion Group
Career Postings
Suggest a Speaker or Topic
Steering Committee
Email Webmaster

Associate Director/Director of Mass Spectrometry

Company: Radikal Therapeutics
Location: North Shore, MA, USA
Job Title:
Associate Director/Director of Mass Spectrometry
To Apply: Send CV and cover letter to

  Radikal Therapeutics has an exciting opportunity in its expanding drug R &D laboratories on the North Shore for a motivated individual to lead a small group providing analytical support to the Medicinal Chemistry and ADME/PK groups in the development of novel small molecules, natural products and related compounds as drug therapies.  
The successful candidate will be responsible for a small team providing analytical
methodologies and structural data to support the pre-clinical development of small
molecules and natural products as drug candidates. In conjunction with other groups, they will be intimately involved in:
  • Development of methodologies for quantitation of drug, active and metabolites in
    biological samples.
  • Identification of metabolites and of metabolic pathways in vitro and in vivo
  • Troubleshooting complex synthetic pathways and reaction products
  • Structural elucidation of impurities, degradation products and isomers
  • Delineation of degradation pathways

Other Duties:
  • Communicating data and findings to colleagues and collaborators, locally and at other sites.
  • General maintenance of laboratory and equipment
  • Justification of new equipment purchases

  • Ph.D. in relevant disciplines, preferably with chemistry background
  • Solid experience in mass spectrometry and structural elucidation
  • Excellent record in method development
  • Comfortable with data handling software and data manipulation

  • Commensurate with experience and responsibilities
  • Paid vacation & Holidays
  • Health insurance
  Contact Information:  
Please send CV and cover letter to

Radikal Therapeutics (RTX) is a multi-national biotechnology firm focused on the discovery and development of transformative pharmaceuticals. With a deep pipeline of therapeutics created in-house, and a paradigm-disruptive discovery engine, we are positioned to remain at the forefront of drug discovery.

Our team of chemists, biologists, immunologists, and drug development professionals have worked together for more than two decades and have built a reputation for leadership in basic science and drug development. The company is developing best-in-class therapeutics in a range of clinical areas including inflammation, ischemia-reperfusion injury, auto-immunity, and prematurity.

Our product platforms include small and large molecule pharmaceuticals that therapeutically restore free radical equilibrium, redirect aberrant signaling pathways in inflammation, manipulate mitochondrial cell death pathways, modulate DNA repair, restore microcirculatory perfusion, and induce specific immunotolerance.

Although varied in their structural targets and directed at diverse clinical needs, our technologies share a unified concept of correcting pathophysiology by endowing agents with multi-functional capacity. This approach yields biological synergies that far outstrip the potency of traditional single-target agents.

RTX makes available its deep and unique experience in pharmaceutical development via its contract services firm Luria Scientific Industries (LSI).